http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023
-
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023
-
AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT
-
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
-
Amgen (AMGN) Responds To FTC Action Regarding Proposed Acquisition Of Horizon Therapeutics (HZNP)
-
AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS
-
Amgen (AMGN) And Tscan Therapeutics (TCRX) Announce Collaboration To Identify Novel Targets In Crohn's Disease
-
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
-
AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE
-
Amgen (AMGN) Reports New PROLIA Data Showing Reduction in Osteoporotic Fracture Risk Compared to Alendronate
-
NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
-
AMGN NOTICE: TOP RANKED ROSEN LAW FIRM Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action – AMGN
-
AMGEN TO PRESENT AT THE 2023 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
-
AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
-
AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS
-
Amgen (AMGN) Wins Patent Appeal On Otezla
-
AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST)
-
ROSEN, A LEADING LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
-
AMGN Investors Have Opportunity to Lead Amgen Inc. Securities Fraud Lawsuit
-
AMGEN TO PRESENT AT THE 33rd ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE
-
AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND
-
AMGEN TO PRESENT AT THE 43RD ANNUAL TD COWEN HEALTHCARE CONFERENCE
-
AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC
-
Amgen (AMGN) Announces Cardiovascular Study To Evaluate Association Between Lipoprotein And Cardiovascular Risk In African Americans
-
AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS
-
Soros buys Horizon Therapeutics, First Horizon, adds to Alphabet, cuts Amazon
-
AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE
-
AstraZeneca (AZN) announces TEZSPIRE approved for self-administration in the US with a new pre-filled pen
-
TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN
-
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
-
Amgen (AMGN) Announces Amjevita now Available in the US
-
AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
-
AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
-
AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE NAMMI THERAPEUTICS TO RECEIVE THE THIRD AMGEN GOLDEN TICKET
-
AMGEN TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
-
Arrowhead (ARWR) Receives $25M Milestone Payment from Amgen (AMGN)
-
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
-
Amgen (AMGN) Says Blincyto Added To Consolidation Chemotherapy Significantly Improves Survival In Adult Patients With Measurable Residual Disease-negative B-ALL
-
BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
-
AMGEN ANNOUNCES 10% INCREASE IN 2023 FIRST QUARTER DIVIDEND
-
AMGEN TO HOST WEBCAST INVESTOR CALL FOLLOWING ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS
-
Amgen (AMGN) Resents New AMG 133 Phase 1 Clinical Data At WCIRDC 2022
-
AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022
-
AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022
-
AMGEN ANNOUNCES WEBCAST OF 2022 EVERCORE ISI HEALTHCARE CONFERENCE
-
Amgen (AMGN) Presents New Repatha Data
-
AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022
-
AMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022
-
Amgen (AMGN) Reports New Phase 2 Data of olpasiran
-
AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS